|
1
|
Xiao Z, Qian L, Liu B and Hao Y:
Meisoindigo for the treatment of chronic myelogenous leukaemia. Br
J Haematol. 111:711–712. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiao Z, Hao Y, Liu B and Qian L: Indirubin
and meisoindigo in the treatment of chronic myelogenous leukemia in
China. Leuk Lymphoma. 43:1763–1768. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji XJ, Liu XM, Li K, Chen RH and Wang LG:
Pharmacological studies of meisoindigo: absorption and mechanism of
action. Biomed Environ Sci. 4:332–337. 1991.PubMed/NCBI
|
|
4
|
Liu XM, Wang LG, Li HY and Ji XJ:
Induction of differentiation and down-regulation of c-myb gene
expression in ML-1 human myeloblastic leukemia cells by the
clinically effective anti-leukemia agent meisoindigo. Biochem
Pharmacol. 51:1545–1551. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao Z, Wang Y, Lu L, et al:
Anti-angiogenesis effects of meisoindigo on chronic myelogenous
leukemia in vitro. Leuk Res. 30:54–59. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CC, Lin CP, Lee YL, Wang GC, Cheng YC
and Liu HE: Meisoindigo is a promising agent with in vitro and in
vivo activity against human acute myeloid leukemia. Leuk Lymphoma.
51:897–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lanotte M, Martin-Thouvenin V, Najman S,
Balerini P, Valensi F and Berger R: NB4, a maturation inducible
cell line with t(15;17) marker isolated from a human acute
promyelocytic leukemia (M3). Blood. 77:1080–1086. 1991.PubMed/NCBI
|
|
8
|
Breitman TR, Selonick SE and Collins SJ:
Induction of differentiation of the human promyelocytic leukemia
cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA.
77:2936–2940. 1980. View Article : Google Scholar
|
|
9
|
Dermime S, Grignani F, Rogaia D,
Liberatore C, Marchesi E and Gambacorti-Passerini C: Acute
promyelocytic leukaemia cells resistant to retinoic acid show
further perturbation of the RAR alpha signal transduction system.
Leuk Lymphoma. 16:289–295. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olsson IL and Breitman TR: Induction of
differentiation of the human histiocytic lymphoma cell line U-937
by retinoic acid and cyclic adenosine 3′:5′-monophosphate-inducing
agents. Cancer Res. 42:3924–3927. 1982.
|
|
11
|
Huang M, Goh LT and Ho PC: Identification
of stereoisomeric metabolites of meisoindigo in rat liver
microsomes by achiral and chiral liquid chromatography/tandem mass
spectrometry. Drug Metab Dispos. 36:2171–2184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang M and Ho PC: Identification of
metabolites of meisoindigo in rat, pig and human liver microsomes
by UFLC-MS/MS. Biochem Pharmacol. 77:1418–1428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang M, Lee YS and Ho PC: Identification
of circulatory and excretory metabolites of meisoindigo in rat
plasma, urine and feces by high-performance liquid chromatography
coupled with positive electrospray ionization tandem mass
spectrometry. Rapid Commun Mass Spectrom. 24:729–741. 2010.
View Article : Google Scholar
|
|
14
|
Collins SJ, Gallo RC and Gallagher RE:
Continuous growth and differentiation of human myeloid leukaemic
cells in suspension culture. Nature. 270:347–349. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sundstrom C and Nilsson K: Establishment
and characterization of a human histiocytic lymphoma cell line
(U-937). Int J Cancer. 17:565–577. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song L and Qian L: Apoptosis inducing
effect of meisoindigo on K562 cells. Zhongguo Zhong Xi Yi Jie He Za
Zhi. 19:353–355. 1999.(In Chinese).
|
|
17
|
Lin RJ, Egan DA and Evans RM: Molecular
genetics of acute promyelocytic leukemia. Trends Genet. 15:179–184.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bedner E, Li X, Gorczyca W, Melamed MR and
Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry.
Cytometry. 35:181–195. 1999. View Article : Google Scholar
|
|
19
|
Cohen GM, Sun XM, Snowden RT, Dinsdale D
and Skilleter DN: Key morphological features of apoptosis may occur
in the absence of internucleosomal DNA fragmentation. Biochem J.
286:331–334. 1992.PubMed/NCBI
|
|
20
|
Hoessel R, Leclerc S, Endicott JA, et al:
Indirubin, the active constituent of a Chinese antileukaemia
medicine, inhibits cyclin-dependent kinases. Nat Cell Biol.
1:60–67. 1999.PubMed/NCBI
|
|
21
|
Huang M, Choo LW and Ho PC:
Characterization of metabolites of meisoindigo in male and female
rat kidney microsomes by high-performance liquid chromatography
coupled with positive electrospray ionization tandem mass
spectrometry. Rapid Commun Mass Spectrom. 22:3835–3845. 2008.
View Article : Google Scholar
|
|
22
|
Fura A: Role of pharmacologically active
metabolites in drug discovery and development. Drug Discov Today.
11:133–142. 2006. View Article : Google Scholar
|
|
23
|
Wee XK, Yeo WK, Zhang B, et al: Synthesis
and evaluation of functionalized isoindigos as antiproliferative
agents. Bioorg Med Chem. 17:7562–7571. 2009. View Article : Google Scholar : PubMed/NCBI
|
